BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/20/2015 5:23:00 PM | Browse: 395 | Download: 518
Publication Name World Journal of Diabetes
Manuscript ID 16262
Country/Territory United Kingdom
2015-01-07 08:37
Peer-Review Started
2015-01-08 20:14
To Make the First Decision
2015-03-06 10:32
Return for Revision
2015-03-11 11:18
2015-03-14 16:06
Second Decision
2015-04-10 18:19
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-04-20 14:42
Articles in Press
2015-04-20 14:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-06-10 09:53
Publish the Manuscript Online
2015-06-20 17:24
ISSN 1948-9358 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, General and Internal
Manuscript Type Editorial
Article Title Incretin manipulation in diabetes management
Manuscript Source Invited Manuscript
All Author List Joseph M Pappachan, AV Raveendran and Rajagopalan Sriraman
Funding Agency and Grant Number
Corresponding author Dr. Joseph M Pappachan, MD, MRCP (London), Department of Endocrinology and Diabetes, New Cross Hospital, the Royal Wolverhampton Hospital NHS Trust, Wolverhampton Road, WV10 0QP Wolverhampton, United Kingdom. drpappachan@yahoo.co.in
Keywords Incretin hormones; Incretin-based therapies; Glucagon-like peptide-1 analogues; Dipeptidyl peptidase-4 inhibitors; Pancreatitis
Core Tip Development of multiple pharmaceutical agents by the manipulation of incretin hormone system provided the global scientific fraternity several drugs for the management of type 2 diabetes mellitus (T2DM) in recent years. These agents, the glucagon-like peptide-1 analogues and dipeptidyl peptidase-4 inhibitors, form the incretin-based therapies that be?nefited T2DM patients with significant reduction of hemoglobin A1c, low risk of hypoglycemia, favorable effects on management of overweight and obesity, and enhanced efficacy in combination regimens for glycemic management with other anti-diabetics. Two recent meta-analyses discarded the concern about elevated pancreatitis risk. The article discusses the incretin-based therapies for the management of T2DM.
Publish Date 2015-06-20 17:24
Citation Pappachan JM, Raveendran AV, Sriraman R. Incretin manipulation in diabetes management. World J Diabetes 2015; 6(6): 774-781
Url http://www.wjgnet.com/1948-9358/full/v6/i6/774.htm
DOI http://dx.doi.org/10.4239/wjd.v6.i6.774
Full Article (PDF) WJD-6-774.pdf
Full Article (Word) WJD-6-774.doc
Manuscript File 16262-Review.doc
Answering Reviewers 16262-Answering reviewers.pdf
Audio Core Tip 16262-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 16262-Conflict-of-interest statement.pdf
Copyright License Agreement 16262-Copyright assignment.pdf
Peer-review Report 16262-Peer-review(s).pdf
Scientific Misconduct Check 16262-Scientific misconduct check.pdf
Scientific Editor Work List 16262-Scientific editor work list.pdf